Caregen Past Earnings Performance
Past criteria checks 1/6
Caregen has been growing earnings at an average annual rate of 8.1%, while the Pharmaceuticals industry saw earnings growing at 11.5% annually. Revenues have been growing at an average rate of 7% per year. Caregen's return on equity is 16.2%, and it has net margins of 45.5%.
Key information
8.1%
Earnings growth rate
8.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 7.0% |
| Return on equity | 16.2% |
| Net Margin | 45.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Why Caregen's (KOSDAQ:214370) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 21
Caregen (KOSDAQ:214370) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Mar 18Recent updates
Why Caregen's (KOSDAQ:214370) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 21Why We're Not Concerned Yet About Caregen Co., Ltd.'s (KOSDAQ:214370) 26% Share Price Plunge
Aug 06Caregen (KOSDAQ:214370) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Mar 18With Caregen Co., Ltd. (KOSDAQ:214370) It Looks Like You'll Get What You Pay For
Mar 05A Look At The Fair Value Of Caregen Co., Ltd. (KOSDAQ:214370)
Apr 20Here's How We Evaluate Caregen Co., Ltd.'s (KOSDAQ:214370) Dividend
Mar 02Caregen (KOSDAQ:214370) Is Growing Earnings But Are They A Good Guide?
Feb 04
Do Its Financials Have Any Role To Play In Driving Caregen Co., Ltd.'s (KOSDAQ:214370) Stock Up Recently?
Jan 14Caregen Co., Ltd. (KOSDAQ:214370) Goes Ex-Dividend Soon
Dec 25Do Insiders Own Lots Of Shares In Caregen Co., Ltd. (KOSDAQ:214370)?
Dec 10Is Caregen Co., Ltd. (KOSDAQ:214370) A Great Dividend Stock?
Nov 19Revenue & Expenses Breakdown
How Caregen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 78,668 | 35,791 | 10,920 | 6,702 |
| 30 Jun 24 | 77,067 | 33,894 | 10,837 | 6,288 |
| 31 Mar 24 | 74,987 | 35,305 | 10,871 | 5,855 |
| 31 Dec 23 | 79,210 | 39,930 | 10,275 | 5,824 |
| 30 Sep 23 | 80,905 | 37,332 | 10,469 | 6,147 |
| 30 Jun 23 | 80,498 | 33,814 | 11,395 | 7,610 |
| 31 Mar 23 | 78,476 | 33,885 | 11,046 | 6,677 |
| 31 Dec 22 | 69,098 | 27,267 | 10,799 | 6,285 |
| 30 Sep 22 | 64,988 | 25,739 | 10,278 | 6,616 |
| 30 Jun 22 | 60,327 | 26,018 | 10,076 | 4,760 |
| 31 Mar 22 | 59,179 | 25,163 | 10,485 | 4,931 |
| 31 Dec 21 | 59,088 | 25,318 | 10,808 | 5,026 |
| 30 Sep 21 | 61,570 | 31,652 | 11,728 | 3,576 |
| 30 Jun 21 | 62,639 | 31,579 | 10,798 | 3,804 |
| 31 Mar 21 | 61,537 | 32,156 | 10,670 | 4,079 |
| 31 Dec 20 | 60,295 | 31,478 | 11,374 | 3,839 |
| 30 Sep 20 | 63,720 | 28,363 | 9,498 | 4,704 |
| 30 Jun 20 | 63,817 | 28,356 | 10,496 | 4,360 |
| 31 Mar 20 | 63,357 | 27,394 | 13,089 | 4,152 |
| 31 Dec 19 | 64,699 | 28,070 | 12,518 | 4,297 |
| 30 Sep 19 | 49,399 | 13,618 | 12,888 | 4,413 |
| 30 Jun 19 | 46,897 | 12,120 | 11,624 | 4,111 |
| 31 Mar 19 | 52,820 | 17,607 | 8,583 | 3,808 |
| 31 Dec 18 | 51,211 | 16,491 | 8,164 | 3,627 |
| 30 Sep 18 | 52,531 | 24,401 | 6,666 | 2,675 |
| 30 Jun 18 | 51,965 | 24,556 | 7,259 | 2,784 |
| 31 Mar 18 | 50,144 | 23,281 | 7,886 | 3,006 |
| 31 Dec 17 | 46,531 | 18,426 | 7,912 | 3,023 |
| 30 Sep 17 | 39,469 | 15,377 | 9,012 | 3,599 |
| 30 Jun 17 | 34,784 | 11,412 | 8,401 | 3,426 |
| 31 Mar 17 | 32,668 | 9,655 | 7,543 | 3,417 |
| 31 Dec 16 | 30,905 | 11,569 | 7,637 | 3,253 |
| 30 Jun 16 | 35,438 | 15,404 | 7,368 | 2,911 |
| 31 Dec 15 | 30,234 | 12,811 | 6,536 | 2,251 |
Quality Earnings: A214370 has a high level of non-cash earnings.
Growing Profit Margin: A214370's current net profit margins (45.5%) are lower than last year (46.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A214370's earnings have grown by 8.1% per year over the past 5 years.
Accelerating Growth: A214370's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A214370 had negative earnings growth (-4.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.6%).
Return on Equity
High ROE: A214370's Return on Equity (16.2%) is considered low.